Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer—The CONKO-008 Phase I Investigation

Background: Primary objective of this present trial was to define the maximum tolerable dose of lapatinib in combination with oxaliplatin, 5-fluorouracil, and folinic acid (OFF) in refractory pancreatic cancer. The secondary objective was to assess the safety and efficacy of lapatinib plus OFF. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Striefler, Jana K., Stieler, Jens M., Neumann, Christopher C. M., Geisel, Dominik, Ghadjar, Pirus, Sinn, Marianne, Malinka, Thomas, Pratschke, Johann, Stintzing, Sebastian, Oettle, Helmut, Riess, Hanno, Pelzer, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409879/
https://www.ncbi.nlm.nih.gov/pubmed/36013144
http://dx.doi.org/10.3390/jcm11164905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409879/
https://www.ncbi.nlm.nih.gov/pubmed/36013144
http://dx.doi.org/10.3390/jcm11164905

Ejemplares similares